Clinical Trial

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-02-01; most recent amendment 2026-06-24.
Status change: Recruiting → Active, Not Recruiting 2025-05-27
Status change: Not Yet Recruiting → Recruiting 2023-10-12
Trial Details
NCT Number NCT05722925
Lead Sponsor OHSU Knight Cancer Institute
Collaborators: Blue Earth Diagnostics, Oregon Health and Science University
Conditions Prostate Cancer
Enrollment 50 participants
Start Date 2023-10-04
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29